SCHEMBL231253

SCHEMBL231253

COC(=O)c1cc(Oc2ccccc2)cc(C(=O)c2ccc(N(C)c3ccc(Cl)cc3)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LTC4S Q16873 5/20 0.42
PGR P06401 1/20 0.42
HPGD P15428 2/20 0.42
SRD5A2 P31213 1/20 0.42
UTS2R Q9UKP6 1/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 1/20 0.40
CASP3 P42574 1/20 0.40
KMT2A Q03164 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
STAT3 P40763 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL233238 0.90 SRD5A2 (0.51) LMNAL3MBTL1LTC4SPGRHPGD
SCHEMBL232232 0.88 LMNA (0.50) LMNAL3MBTL1LTC4SHPGDSRD5A2
SCHEMBL231300 0.87 ALDH1A1 (0.40) LMNAL3MBTL1LTC4SPGRHPGD
SCHEMBL231299 0.87 ALDH1A1 (0.40) LMNAL3MBTL1LTC4SPGRHPGD
SCHEMBL231059 0.87 LTC4S (0.56) LTC4S
SCHEMBL27850790 0.86 L3MBTL1 (0.50) LMNAL3MBTL1LTC4SHPGDMAPT
SCHEMBL232161 0.86 HPGD (0.42) LMNAL3MBTL1LTC4SHPGDUSP2
SCHEMBL232400 0.85 HPGD (0.46) LMNAL3MBTL1LTC4SHPGDSRD5A2
SCHEMBL2743161 0.84 LMNA (0.48) LMNAL3MBTL1LTC4SHPGDSRD5A2
SCHEMBL232108 0.84 MAPT (0.44) LMNAL3MBTL1LTC4SHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406220-A1 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS Biolipox AB (SE) 2012-01-18 EP disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
WO-2010103279-A1 BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS BIOLIPOX AB (SE) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R LMNA 1141/4885L3MBTL1 324/4885LTC4S 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.